From Wikipedia, the free encyclopedia
NicOx S.A. is a French pharmaceutical company. Its headquarters are at Sophia Antipolis (U.S. headquarters in Warren, New Jersey, opened in October 2007). Louis Ignarro, corecipient of the 1998 Nobel Prize in Physiology or Medicine for demonstrating the signalling properties of nitric oxide, is a member of the scientific committee of the company.
The company focuses on the uses of the medical properties of nitric oxide. It is developing an anti-inflammatory drug, naproxcinod, of the CINOD (COX-inhibiting nitric oxide donator) class for the treatment of osteoarthritis. This class of drugs was first described by John Wallace[1] and colleagues.[2] If the presently running phase III clinical trials are successful, naproxcinod could replace many existing non-steroidal anti-inflammatory drugs.
The market capitalisation of the company is $ 1 billion (January 2008). It is listed on Euronext, the French stock exchange and is part of the CAC Mid 100 stock market index. It will be part of the SBF 120 index from 18th June 2007. Oppenheimer Funds is its first shareholder with 25 % of its capital.
[edit] External links
